Liverpool orthopaedic products manufacturer and distributor Algeos sees pre-tax profits more than double to almost £400,000 and plans to grow the business further both in the UK and overseas. Tony McDonough reports
Liverpool orthopaedic products manufacturer and distributor Algeos says its annual pre-tax profits have almost doubled despite a slight dip in revenues.
Originally founded in Liverpool in 1881 by John Algeo as a leather dealing business, Algeos is now a manufacturer of podiatry, orthotics and footwear products and technologies. It has a global customer base and supplies hundreds of NHS trusts.
It also supplies its products to 60 countries around the world, in particular Asia Pacific, the Middle East, and Africa regions. Its Algeos Australia base in Melbourne serves Australasia.
In 2022, LBN reported that Algeos had secured a £900,000 deal to supply products across the Middle East. This deal included the supply of diabetic footwear, orthotic and prosthetic materials, foot orthotics and other consumables.
In its accounts for the 12 months to December 31, 2025, posted on Companies House, Algeos is reporting revenues of £11.8m, slightly down on £11.9m in 2024. However, pre-tax profits surged to £399,000 from £182,000 in 2024.
Principal shareholders are Max Sheridan, who is also the managing director, and Diana Sheridan. Max’s shareholding is more than 50% and they shared dividends of £73,000 in 2025.
READ MORE: Wirral clinical trials venture targets global expansion
Writing in the annual report, Max said: “The company has a strategic plan to grow the business. The business continues to focus on growing the UK technical and online sales, alongside increasing international sales by increasing the network of distributors.
“In addition, the business has recently entered into new adjacent markets with existing product lines to increase the diversity of the business… The company invested significantly in the infrastructure of a premises in 2025.”